Patents Assigned to NOVALIQ GmbH
-
Patent number: 11896559Abstract: The present disclosure provides methods of treatment using ophthalmic compositions comprising semifluorinated alkanes for keratoconjunctivitis sicca and/or Meibomian gland dysfunction, which methods provide for the enrichment of an ophthalmic tissue in the semifluorinated alkane, and optionally methods of delayed release of the semifluorinated alkane from the enriched ophthalmic tissue to the surface of the cornea and/or conjunctiva, and/or to the Meibomian gland.Type: GrantFiled: October 3, 2018Date of Patent: February 13, 2024Assignee: NOVALIQ GMBHInventors: Bernhard Günther, Frank Löscher, Hartmut Voss, Sonja Krösser, Kirsten Eickhoff, Daniela Willen, Markus Beier, Thomas Schlüter
-
Publication number: 20230330056Abstract: The invention provides novel compositions comprising semifluorinated alkanes and at least one compound sensitive or prone to oxidation. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue. The invention further provides kits comprising such compositions.Type: ApplicationFiled: January 19, 2023Publication date: October 19, 2023Applicant: Novaliq GmbHInventors: Bernhard GÜNTHER, Dieter SCHERER, Anthony PETTIGREW, Bastian THEISINGER, Sonja THEISINGER
-
Patent number: 11723861Abstract: The invention provides a pharmaceutical composition for use in the prevention or therapy of glaucoma, increased intraocular pressure, ocular hypertension and/or a symptom associated therewith, wherein—the composition comprises latanoprost and a liquid vehicle comprising a semifluorinated alkane; and—the composition is administered to the eye of a subject; and—the amount of latanoprost administered in a single dose per eye is in the range of from about 0.5 to 1.4 ?g.Type: GrantFiled: September 25, 2018Date of Patent: August 15, 2023Assignee: NOVALIQ GMBHInventors: Bernhard Günther, Frank Löscher, Kirsten Eickhoff
-
Patent number: 11684589Abstract: The present invention provides a pharmaceutical composition comprising 1-perfluorohexyl-octane (F6H8) for use in the therapy, treatment, prevention or amelioration of anterior or posterior blepharitis, preferably posterior blepharitis or symptoms associated therewith. Furthermore, the present invention provides a pharmaceutical kit for the therapy of anterior or posterior blepharitis or symptoms associated therewith.Type: GrantFiled: September 20, 2017Date of Patent: June 27, 2023Assignee: NOVALIQ GMBHInventors: Bernhard Günther, Frank Löscher, Sonja Krösser
-
Publication number: 20230139672Abstract: The invention provides liquid compositions in the form of physically stable emulsions comprising a semifluorinated alkane. The semifluorinated alkane is comprised in the dispersed phase, which may also include an active pharmaceutical ingredient. One of the preferred active ingredients is propofol. The compositions are optionally heat sterilisable and can be used for pharmaceutical or cosmetic product applications, and administered topically, intravenously, or via other routes.Type: ApplicationFiled: December 23, 2022Publication date: May 4, 2023Applicant: NOVALIQ GMBHInventors: Bastian THEISINGER, Sonja THEISINGER, Bernhard GÜNTHER
-
Patent number: 11583513Abstract: The invention provides novel compositions comprising semifluorinated alkanes and at least one compound sensitive or prone to oxidation. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue. The invention further provides kits comprising such compositions.Type: GrantFiled: February 6, 2020Date of Patent: February 21, 2023Assignee: NOVALIQ GMBHInventors: Bernhard Günther, Dieter Scherer, Anthony Pettigrew
-
Patent number: 11576893Abstract: The present invention relates to pharmaceutical compositions comprising the selective beta 1 (B1)-receptor blocker nebivolol and/or a pharmaceutically acceptable salt thereof and a liquid vehicle comprising a semifluorinated alkane. The pharmaceutical composition of the present invention is useful for topical administration, for example ophthalmic topical administration and for use in the treatment of glaucoma, increased intraocular pressure, ocular hypertension and/or a symptom associated therewith.Type: GrantFiled: March 1, 2019Date of Patent: February 14, 2023Assignee: NOVALIQ GMBHInventors: Frank Löscher, Kirsten Eickhoff, Diana Strehl
-
Publication number: 20230043641Abstract: The invention provides pharmaceutical compositions comprising about 0.05 to 0.1% (w/v) cyclosporine dissolved in 1-perfluorobutyl-pentane for use in the topical treatment of dry eye disease and provides for dosing and treatment methods thereof. The invention further provides kits comprising such compositions.Type: ApplicationFiled: September 19, 2022Publication date: February 9, 2023Applicant: NOVALIQ GMBHInventors: Markus BEIER, Jörg HAISSER, Alice MEIDES, Sonja KRÖSSER, Hartmut VOSS, Frank LÖSCHER, Bernhard GÜNTHER
-
Publication number: 20220354926Abstract: The present invention relates to compositions in the form of a clear solution comprising ciclosporin with low residual water content and 1-perfluorobutyl-pentane. The compositions may be used for topical administration to the eye.Type: ApplicationFiled: July 25, 2022Publication date: November 10, 2022Applicant: NOVALIQ GMBHInventors: Frank LÖSCHER, Ralf GRILLENBERGER, Johan ENGBLOM
-
Patent number: 11413323Abstract: The invention provides ophthalmic compositions comprising about 0.1 % (w/v) cyclosporine dissolved in 1-(perfluorobutyl)pentane for use in the topical treatment of dry eye disease. The invention further provides kits comprising such compositions for the same use.Type: GrantFiled: April 12, 2021Date of Patent: August 16, 2022Assignee: NOVALIQ GMBHInventors: Chiara Silvana Leo, Sonja Krösser, Thomas Schlüter, Alice Meides
-
Patent number: 11400132Abstract: The present invention relates to compositions in the form of a clear solution comprising ciclosporin with low residual water content and 1-perfluorobutyl-pentane. The compositions may be used for topical administration to the eye.Type: GrantFiled: October 13, 2020Date of Patent: August 2, 2022Assignee: NOVALIQ GMBHInventors: Frank Löscher, Ralf Grillenberger, Johan Engblom
-
Patent number: 11357738Abstract: The present invention is directed to compositions comprising semifluorinated compounds and their use as medicaments for topical administration to the eye.Type: GrantFiled: May 14, 2020Date of Patent: June 14, 2022Assignee: NOVALIQ GMBHInventors: Dieter Scherer, Ralf Grillenberger, Frank Löscher, Hartmut Voss
-
Patent number: 11324757Abstract: The invention provides novel pharmaceutical compositions for the treatment of increased intraocular pressure based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble prostaglandin analogues. The compositions can be administered topically into the eye. The invention further provides kits comprising such compositions.Type: GrantFiled: December 31, 2019Date of Patent: May 10, 2022Assignee: NOVALIQ GMBHInventors: Bastian Theisinger, Sonja Theisinger, Bernhard Günther
-
Patent number: 11278503Abstract: A pharmaceutical composition comprising a semifluorinated alkane of formula (I): F(CF2)n(CH2)mH, wherein n is an integer from 4 to 6, and m is an integer from 5 to 8, for use in the treatment or prevention of a disease or condition relating to an ocular surface of an eye of an individual, wherein the individual is a contact lens wearer, and wherein the contact lens is a hydro gel contact lens and the composition is administered topically to a surface of the eye of the individual before the contact lens is inserted to the eye of the individual and/or during contact lens wear and/or after the contact lens has been removed from the eye of the individual, or wherein the contact lens is a silicone hydrogel contact lens and the composition is administered topically to a surface of the eye of the individual after the contact lens has been removed from the eye of the individual.Type: GrantFiled: May 9, 2018Date of Patent: March 22, 2022Assignee: NOVALIQ GMBHInventors: Bernhard Günther, Markus Beier, Oliver Schlüter
-
Patent number: 11273174Abstract: The present invention relates to compositions comprising molecular iodine and a vehicle comprising a semifluorinated alkane. The compositions of the invention may be used to treat or prevent diseases or conditions caused by, or associated with microorganisms.Type: GrantFiled: April 20, 2018Date of Patent: March 15, 2022Assignee: NOVALIQ GMBHInventors: Frank Löscher, Ralf Grillenberger
-
Publication number: 20210340248Abstract: The invention provides novel compositions of antibodies based on liquid vehicles selected from semifluorinated alkanes. The use of these vehicles provides for improved stability and shelf-life of antibodies and their derivatives. The compositions are useful for topical administration or for parenteral injection.Type: ApplicationFiled: May 14, 2021Publication date: November 4, 2021Applicant: NOVALIQ GMBHInventors: Bernhard Günther, Dieter Scherer, Anthony Pettigrew, Gesche Graf
-
Patent number: 11160865Abstract: The invention provides novel pharmaceutical compositions based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble and/or hydrolytically sensitive drug substances. The compositions are designed as suspensions and have superior physical properties which make them highly useful as pharmaceutical delivery systems. The compositions may be administered topically into the eye, or injected via the subcutaneous or intramuscular route. The invention further provides kits comprising such compositions.Type: GrantFiled: April 4, 2018Date of Patent: November 2, 2021Assignee: NOVALIQ GMBHInventors: Bastian Theisinger, Sonja Theisinger, Bernhard Günther
-
Patent number: 11154513Abstract: The present invention is directed to certain semifluorinated compounds and to compositions comprising such compounds. The invention further provides the use of the compounds and of the compositions as medicaments for topical administration to the eye.Type: GrantFiled: September 29, 2016Date of Patent: October 26, 2021Assignee: NOVALIQ GMBHInventors: Dieter Scherer, Ralf Grillenberger, Frank Löscher, Hartmut Voss
-
Publication number: 20210100904Abstract: The invention provides liquid or semi-solid pharmaceutical compositions for topical administration comprising a semifluorinated alkane. The compositions are useful for the delivery of active ingredients into the deep layers of the skin or skin appendages. Various active ingredients may be incorporated, such as immunosuppressants, antiinfectives, antifungal agents, antiinflammatory agents, and retinoids.Type: ApplicationFiled: October 16, 2020Publication date: April 8, 2021Applicant: NOVALIQ GMBHInventors: Bernhard GUNTHER, Bastian THEISINGER, Sonja THEISINGER, Dieter SCHERER
-
Patent number: RE49758Abstract: The invention provides novel compositions of bioactive polypeptides and proteins with improved stability and shelf-life. The compositions are based on liquid vehicles selected from semifluorinated alkanes. These vehicles are remarkably effective in protecting polypeptides and proteins from degradation and/or aggregation. The compositions are useful for topical administration, e.g. into an eye, or by parenteral injection, e.g. via the subcutaneous or intramuscular route.Type: GrantFiled: January 21, 2021Date of Patent: December 19, 2023Assignee: NOVALIQ GMBHInventors: Bernhard Günther, Bastian Theisinger, Sonja Theisinger, Dieter Scherer, Clive Wilson, Anthony Pettigrew, Annette Hüttig